Cancer Family
Epithelial Neoplasm
CI-CAN-00000016Explore in graph →
Non-malignant7,531 active trials118 approved drugs1,152 evidence items
- NCIt
- C3709
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000016Explore in graph →
Clinical trials
26,887 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03919383 | Phase II of Lenvatinib Plus Toripalimab for Advanced HCC | withdrawn | Phase 2 | 0 | Sun Yat-sen UniversityOTHER | 1 | Jun 3, 2019 | clinicaltrials |
| NCT03432676 | Epacadostat and Pembrolizumab in Treating Participants With Advanced Pancreatic Cancer | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | May 30, 2019 | clinicaltrials |
| NCT03908333 |
| High Dose Ascorbic Acid and Nanoparticle Paclitaxel Protein Bound and Cisplatin and Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer |
| withdrawn |
| Phase 1 / Phase 2 |
| 0 |
| Medical College of WisconsinOTHER |
| 1 |
| May 30, 2019 |
| clinicaltrials |
| NCT03121417 | Nivolumab in Treating Patients With Advanced Metastatic Non-small Cell Lung Cancer | withdrawn | Phase 2 | 0 | Emory UniversityOTHER | 1 | May 21, 2019 | clinicaltrials |
| NCT03775707 | Lenvatinib Plus PD-1 Antibody for Intermediate-stage HCC Beyond Up-to-seven Criteria | withdrawn | Phase 2 | 0 | Shi MingOTHER | 1 | May 6, 2019 | clinicaltrials |
| NCT03780634 | HAIC Plus PD-1 Antibody vs HAIC Plus Sorafenib for Advanced HCC | withdrawn | Phase 2 | 0 | Sun Yat-sen UniversityOTHER | 1 | May 6, 2019 | clinicaltrials |
| NCT03803254 | HAIC Plus Lenvatinib and PD-1 Antibody Versus HAIC Plus Lenvatinib for Advanced HCC | withdrawn | Phase 2 | 0 | Sun Yat-sen UniversityOTHER | 1 | May 6, 2019 | clinicaltrials |
| NCT03782831 | TACE Plus PD-1 Antibody vs TACE Alone for Unresectable HCC | withdrawn | Phase 2 | 0 | Sun Yat-sen UniversityOTHER | 1 | May 2, 2019 | clinicaltrials |
| NCT03644589 | Effect of Pembrolizumab and Cisplatin on Metastatic, Locally Recurrent or Inoperable Triple-Negative Breast Cancer | withdrawn | Phase 2 | 0 | University of WashingtonOTHER | 1 | Apr 26, 2019 | clinicaltrials |
| NCT03325465 | Neoadjuvant Pembrolizumab + Epacadostat Prior to Curative Surgical Care for Squamous Cell Carcinoma of the Head and Neck | withdrawn | Phase 2 | 0 | University of ChicagoOTHER | 1 | Apr 22, 2019 | clinicaltrials |
| NCT03746249 | Phase II of Lenvatinib Plus PD-1 Antibody for Advanced HCC | withdrawn | Phase 2 | 0 | Sun Yat-sen UniversityOTHER | 1 | Apr 17, 2019 | clinicaltrials |
| NCT03419559 | Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) In Combo With Durvalumab in Non-Small Cell Lung Cancer | withdrawn | Phase 2 | 0 | Iovance Biotherapeutics, Inc.INDUSTRY | 1 | Apr 16, 2019 | clinicaltrials |
| NCT03114280 | Pembrolizumab and Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma (PICH Study)(PICH) | withdrawn | Phase 1 / Phase 2 | 0 | Centre Antoine LacassagneOTHER | 1 | Apr 8, 2019 | clinicaltrials |
| NCT02542930 | Abscopal Effect for Metastatic Non-small Cell Lung Cancer. | withdrawn | Phase 2 | 0 | Zhejiang Provincial People's HospitalOTHER | 0 | Mar 26, 2019 | clinicaltrials |
| NCT02542137 | Abscopal Effect for Metastatic Small Cell Lung Cancer | withdrawn | Phase 2 | 0 | Zhejiang Provincial People's HospitalOTHER | 0 | Mar 21, 2019 | clinicaltrials |
| NCT02948101 | PD 0360324 and Cyclophosphamide in Treating Patients With Recurrent High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 12, 2019 | clinicaltrials |
| NCT02355431 | Itacitinib in Combination With Erlotinib in Non Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations | withdrawn | Phase 2 | 0 | Incyte CorporationINDUSTRY | 1 | Mar 8, 2019 | clinicaltrials |
| NCT03346304 | Photodynamic Therapy for the Prevention of Lung Cancer(PEARL) | withdrawn | Phase 2 / Phase 3 | 0 | University College, LondonOTHER | 0 | Feb 1, 2019 | clinicaltrials |
| NCT03147196 | Bicalutamide and Raloxifene Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery | withdrawn | Phase 2 | 0 | Mayo ClinicOTHER | 0 | Jan 22, 2019 | clinicaltrials |
| NCT03323710 | Study of Propranolol Plus Sunitinib in First-line Treatment of Metastatic Renal Cell Carcinoma | withdrawn | Phase 2 | 0 | Military Institute od Medicine National Research InstituteOTHER | 1 | Jan 9, 2019 | clinicaltrials |
| NCT03419130 | Radiation Therapy and Pembrolizumab in Treating Patients With Localized Urothelial Bladder Cancer | withdrawn | Phase 2 | 0 | University of California, San FranciscoOTHER | 1 | Dec 7, 2018 | clinicaltrials |
| NCT00621036 | Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma | withdrawn | Phase 2 | 0 | University of Texas Southwestern Medical CenterOTHER | 1 | Nov 26, 2018 | clinicaltrials |
| NCT03226236 | Vaccination With Dendritic Cells Pulsed With Autologous Tumor Homogenate in Combination With HD-IL2 and Immunomodulating Radiotherapy in Metastatic RCC(RENALVax-2) | withdrawn | Phase 2 | 0 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | Nov 13, 2018 | clinicaltrials |
| NCT02623595 | A Study of SBRT in Combination With rhGM-CSF for Stage IV NSCLC Patients Who Failed in Second-line Chemotherapy | withdrawn | Phase 2 | 0 | Wuhan UniversityOTHER | 1 | Oct 15, 2018 | clinicaltrials |
| NCT02763761 | An Investigational Study of Infliximab With Prednisone or Methylprednisolone Versus Prednisone Combination Treatment in Immune Related or Severe Diarrhea in Patients Treated With Yervoy and/or Opdivo | withdrawn | Phase 2 | 0 | Bristol-Myers SquibbINDUSTRY | 1 | Oct 9, 2018 | clinicaltrials |
| NCT03220009 | Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Oct 3, 2018 | clinicaltrials |
| NCT02672358 | Study of Efficacy and Safety of Dabrafenib and Trametinib Combination Therapy in Japanese Patients With BRAF V600E Stage IV NSCLC | withdrawn | Phase 2 | 0 | Novartis PharmaceuticalsINDUSTRY | 0 | Aug 10, 2018 | clinicaltrials |
| NCT03370159 | CPI-613 and Docetaxel in Treating Patients With Stage IIIB or IV Non-small Cell Lung Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Wake Forest University Health SciencesOTHER | 1 | Aug 1, 2018 | clinicaltrials |
| NCT03240393 | Study of Oral cMET Inhibitor INC280 in Chinese Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer (NSCLC) | withdrawn | Phase 2 | 0 | Novartis PharmaceuticalsINDUSTRY | 0 | Jul 26, 2018 | clinicaltrials |
| NCT03326258 | Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery | withdrawn | Phase 1 / Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | Jul 18, 2018 | clinicaltrials |
| NCT02943603 | A Study of Perioperative mFOLFOX6 Plus Pembrolizumab in Patients With Potentially Resectable Adenocarcinoma of the Gastroesophageal Junction (GEJ) and Stomach | withdrawn | Phase 2 | 0 | Weijing Sun, MD, FACPOTHER | 1 | Jul 13, 2018 | clinicaltrials |
| NCT01610544 | 18F FLT Imaging Studies of Treatment Response for Lung Cancer and Thymoma | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | Jul 5, 2018 | clinicaltrials |
| NCT02014545 | Evaluation of Lucanthone to Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung Cancer | withdrawn | Phase 2 | 0 | Wake Forest University Health SciencesOTHER | 1 | Jul 5, 2018 | clinicaltrials |
| NCT03149159 | Investigator-Initiated Trial of Combined Ipilimumab, Nivolumab and Stereotactic Radiation in Patients With Metastatic Clear-Cell RCC (ccRCC) Who Have Failed Treatment With Single-Agent Nivolumab | withdrawn | Phase 2 | 0 | Medical University of South CarolinaOTHER | 1 | Jun 18, 2018 | clinicaltrials |
| NCT02702960 | Sequential, Related Donor Partial Liver Transplantation Followed by Bone Marrow Transplantation for Hepatocellular Carcinoma (HCC) | withdrawn | Phase 2 | 0 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jun 15, 2018 | clinicaltrials |
| NCT03023904 | Nivolumab in Treating Patients With Stage IV or Recurrent Lung Cancer With High Mutation Loads | withdrawn | Phase 2 | 0 | Vanderbilt-Ingram Cancer CenterOTHER | 0 | Apr 25, 2018 | clinicaltrials |
| NCT03004105 | MEDI4736 With Selumetinib for KRAS Mutant Non-Small Cell Lung Cancer (NSCLC) | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Mar 16, 2018 | clinicaltrials |
| NCT02962804 | Combination Radiation and PD-1 Inhibition in Metastatic or Recurrent Renal Cell Carcinoma (RCC) | withdrawn | Phase 2 | 0 | University of Kansas Medical CenterOTHER | 1 | Mar 5, 2018 | clinicaltrials |
| NCT02908165 | Randomized Phase II Trial of Chemoembolization and Sorafenib | withdrawn | Phase 2 | 0 | Yale UniversityOTHER | 1 | Jan 10, 2018 | clinicaltrials |
| NCT03307941 | Assessment of Metabolic & Path Response w/ RCT & ImT Before Surgery in Locally Advanced Esoph and Gastro-esoph Jction CA(ARTEMIS-Eso) | withdrawn | Phase 1 / Phase 2 | 0 | Jules Bordet InstituteOTHER | 1 | Dec 19, 2017 | clinicaltrials |
| NCT02406508 | Sequential Melphalan for Use With Hepatic Delivery System Treatment Followed by Sorafenib in Patients With Unresectable HCC | withdrawn | Phase 2 | 0 | Delcath Systems Inc.INDUSTRY | 1 | Dec 18, 2017 | clinicaltrials |
| NCT03130764 | Durvalumab and Tremelimumab for Adjuvant Therapy of Resected NSCLC | withdrawn | Phase 2 | 0 | Columbia UniversityOTHER | 0 | Dec 6, 2017 | clinicaltrials |
| NCT02947113 | Combination of Platinum Doublets and Hypofractionated Radiotherapy in NSCLC(HYPOLAN) | withdrawn | Phase 2 | 0 | The Netherlands Cancer InstituteOTHER | 0 | Nov 30, 2017 | clinicaltrials |
| NCT02298595 | Cetuximab, Cisplatin and BYL719 for HPV-Associated Oropharyngeal Squamous Cell Carcinoma | withdrawn | Phase 1 / Phase 2 | 0 | Julie E. Bauman, MD, MPHOTHER | 0 | Nov 13, 2017 | clinicaltrials |
| NCT02405910 | Ph2 Nab-paclitaxel With Gemcitabine to Determine Efficacy in Advanced Non-squamous NSCLC. | withdrawn | Phase 2 | 0 | West Virginia UniversityOTHER | 1 | Nov 6, 2017 | clinicaltrials |
| NCT03143491 | Study of SOR007 Ointment for Cervical Intraepithelial Neoplasia (CIN) | withdrawn | Phase 2 | 0 | DFB Soria, LLCINDUSTRY | 0 | Oct 18, 2017 | clinicaltrials |
| NCT02876081 | Phase II Study of Afatinib as Third- or Further-line Treatment for Patients With Stage IV Bronchial Adenocarcinoma, Harboring Wild-type EGFR, Expressing the Neurotensin - Neurotensin Receptor Complex(THEN) | withdrawn | Phase 2 | 0 | Fondation Hôpital Saint-JosephOTHER | 1 | Sep 11, 2017 | clinicaltrials |
| NCT02924233 | Sym004 in Combination With Nivolumab Versus Nivolumab Monotherapy in EGFR-amplified Squamous Non-Small Cell Lung Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Symphogen A/SINDUSTRY | 0 | Aug 28, 2017 | clinicaltrials |
| NCT02425072 | NovoTTF-100A Therapy for Refractory CNS Involved Small Cell Lung Cancer | withdrawn | Phase 2 | 0 | John VillanoOTHER | 1 | Aug 10, 2017 | clinicaltrials |
| NCT00257335 | Intensity-Modulated Radiotherapy for Recurrent Head and Neck Cancer | withdrawn | Phase 2 | 0 | Nilam RamsinghaniOTHER | 0 | Jul 31, 2017 | clinicaltrials |
Data updated 23 days agoSource updated Jun 3, 2019source: clinicaltrials